Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Standard
Personalized circulating tumor DNA in patients with hepatocellular carcinoma : a pilot study. / Pommergaard, H. C.; Yde, C. W.; Ahlborn, L. B.; Andersen, C. L.; Henriksen, T.; Hasselby, J. P.; Rostved, A. A.; Sorensen, C. L.; Rohrberg, K. S.; Nielsen, F. C.; Rasmussen, A.
I: Molecular Biology Reports, Bind 49, Nr. 2, 2022, s. 1609-1616.Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Personalized circulating tumor DNA in patients with hepatocellular carcinoma
T2 - a pilot study
AU - Pommergaard, H. C.
AU - Yde, C. W.
AU - Ahlborn, L. B.
AU - Andersen, C. L.
AU - Henriksen, T.
AU - Hasselby, J. P.
AU - Rostved, A. A.
AU - Sorensen, C. L.
AU - Rohrberg, K. S.
AU - Nielsen, F. C.
AU - Rasmussen, A.
PY - 2022
Y1 - 2022
N2 - Background Mutational analysis of circulating tumor DNA (ctDNA) can potentially be used for early detection of recurrence after resection for hepatocellular carcinoma (HCC). Mutations from tumor may be identified in plasma as an early sign of recurrence. We conducted a pilot study investigating if somatic mutations could be detected in plasma in patients undergoing liver resection for HCC and in patients with advanced non-resectable HCC. Methods and results We prospectively included patients undergoing curative liver resection for HCC. Tumor tissue was investigated with whole exome sequencing and preoperative blood samples were evaluated for ctDNA using targeted next-generation sequencing (NGS) with TruSight Oncology 500 including 523 cancer-associated genes. Subsequently, the method was evaluated in patients with advanced HCC. We included eight patients curatively resected for HCC, where tumor tissue mutations were identified in seven patients. However, only in one patient tumor specific mutations were found in the preoperative blood sample. In all three patients with advanced HCC, tumor mutations were detected in the blood. Conclusions In patients with resectable HCC, ctDNA could not be reliably detected using the applied targeted NGS method. In contrast, ctDNA was detected in all patients with advanced HCC. Small tumors, tumor heterogeneity and limited sequencing coverage may explain the lack of detectable ctDNA.
AB - Background Mutational analysis of circulating tumor DNA (ctDNA) can potentially be used for early detection of recurrence after resection for hepatocellular carcinoma (HCC). Mutations from tumor may be identified in plasma as an early sign of recurrence. We conducted a pilot study investigating if somatic mutations could be detected in plasma in patients undergoing liver resection for HCC and in patients with advanced non-resectable HCC. Methods and results We prospectively included patients undergoing curative liver resection for HCC. Tumor tissue was investigated with whole exome sequencing and preoperative blood samples were evaluated for ctDNA using targeted next-generation sequencing (NGS) with TruSight Oncology 500 including 523 cancer-associated genes. Subsequently, the method was evaluated in patients with advanced HCC. We included eight patients curatively resected for HCC, where tumor tissue mutations were identified in seven patients. However, only in one patient tumor specific mutations were found in the preoperative blood sample. In all three patients with advanced HCC, tumor mutations were detected in the blood. Conclusions In patients with resectable HCC, ctDNA could not be reliably detected using the applied targeted NGS method. In contrast, ctDNA was detected in all patients with advanced HCC. Small tumors, tumor heterogeneity and limited sequencing coverage may explain the lack of detectable ctDNA.
KW - HCC
KW - ctDNA
KW - NGS
KW - Circulating tumor DNA
KW - Liver resection
KW - HETEROGENEITY
KW - DIAGNOSIS
KW - CIRRHOSIS
KW - NODULES
KW - CANCER
U2 - 10.1007/s11033-021-06962-1
DO - 10.1007/s11033-021-06962-1
M3 - Letter
C2 - 34811635
VL - 49
SP - 1609
EP - 1616
JO - Molecular Biology Reports
JF - Molecular Biology Reports
SN - 0301-4851
IS - 2
ER -
ID: 314448879